ADC Therapeutics' experimental compound, ZYNLONTA, in conjunction with rituximab, has achieved its main goal in the Phase 3 LOTIS-5 trial for patients battling relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Despite the positive efficacy outcomes, the company's stock witnessed a substantial drop in value on Thursday, fueled by concerns over the drug's safety profile, which included an elevated incidence of serious and Grade 5 adverse events. This development has initiated critical discussions with the U.S. Food and Drug Administration (FDA) regarding the benefit-risk assessment of the treatment.

ADC Therapeutics Reveals LOTIS-5 Trial Outcomes and Future Plans

On June 4, 2026, ADC Therapeutics announced the pivotal results from its Phase 3 LOTIS-5 study. The trial, designed to confirm the efficacy of ZYNLONTA when administered with rituximab, successfully met its primary objective: an extension in progression-free survival for individuals suffering from relapsed or refractory diffuse large B-cell lymphoma. Furthermore, the combination therapy did not negatively impact overall survival and demonstrated superior complete response rates and extended durations of complete response compared to the control group's treatment.

Specifically, patients receiving the ZYNLONTA-rituximab combination experienced a median progression-free survival of 6.1 months, a notable improvement over the 4.7 months observed in the R-GemOx control arm. The overall response rate for the investigational combination was 58.1%, surpassing the 45.2% of R-GemOx, with complete response rates standing at 39.5% versus 26.7% respectively. The median duration of response was also longer in the ZYNLONTA group, reaching 9.2 months compared to 7.7 months in the control arm. For those achieving a complete response, the median duration was 16.8 months, significantly higher than the 12.3 months seen in the R-GemOx group. Impressively, 48.5% of patients in complete remission maintained this status at 24 months, in stark contrast to 16.7% in the control arm.

However, the study also highlighted a more frequent occurrence of hematologic adverse events in the control group, while infections, hepatotoxicity, and edema or effusion were more prevalent in the ZYNLONTA arm. Critically, serious adverse events, treatment discontinuations due to adverse events, and Grade 5 events were observed at higher rates in the ZYNLONTA cohort. The company noted that the majority of Grade 5 treatment-emergent adverse events in the test arm occurred in patients aged 75 years or older.

In light of these findings, Mohamed Zaki, Chief Medical Officer of ADC Therapeutics, stated the company's intention to engage in further discussions with the U.S. FDA to outline the next steps for the ZYNLONTA-rituximab combination. A pre-sBLA meeting is scheduled for August, with a planned sBLA submission in the fourth quarter of 2026. Simultaneously, ADC Therapeutics is actively exploring alternative strategies to maximize value.

Following this announcement, ADC Therapeutics' stock (ADCT) saw a substantial decrease, falling by 49.68% to $1.55 during premarket trading on Thursday.

This news underscores the complex balance between promising clinical efficacy and the imperative of drug safety in pharmaceutical development. While ZYNLONTA has shown significant benefits for DLBCL patients, the increased adverse events necessitate thorough regulatory review and careful consideration for patient selection. The market's reaction reflects the sensitivity of investors to potential safety concerns, even when coupled with strong therapeutic outcomes. The upcoming discussions with the FDA will be crucial in determining the path forward for ZYNLONTA and its impact on the future of lymphoma treatment.